Success for Allergan CGRP drug during phase 3 migraine trial
Co-primary endpoints were met when it came to a phase 3 trial of Allergan’s oral CGRP drug ubrogenpant. In the two hours after dosing, the drug provided much more relief than the placebo to intense migraine patients. On the other hand, the size of the effect, and the cases of increased liver enzymes leaves room for doubt about its forecast.
Time To See A Biotech Rally?
One company has put together a leading management team, a strong pipeline of therapies, and holds a key biotechnology that could impact millions of people at risk. With the recent market pull-back, now could be an important time to be paying even closer attention to this emerging biotech company.
AstraZeneca Focuses on $500M Buyout
Monotherapy development of a PD-1 drug has stopped according to AstraZeneca. The drug acquired a $500 million biotech buyout. There is a new focus of AstraZeneca’s takeover of Amplimmune, and this is MEDI0680.